Nevertheless, generation of autologous CAR T cell products is extremely time consuming and costly, prompting researchers to explore alternative strategies to overcome these limitations.
In this issue ofreport results of part A of the phase 1 UNIVERSAL clinical trial, which evaluated ALLO-715, an allogeneic off-the-shelf anti-BCMA CAR T cell product. The study demonstrated that administering these off-the-shelf CAR T cells is feasible, and that the therapy has clear anti-malignancy activity in multiple myeloma.
theNCI Pstx. Crbu.
theNCI Thanks for the pay wall.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: nbcbayarea - 🏆 596. / 51 Read more »
Source: bbchealth - 🏆 143. / 63 Read more »